Zimmer issues first growth forecasts:
This article was originally published in Clinica
Executive Summary
Zimmer expects its first 18 months as an independent company to generate sales growth of between 8-11% and income after separation costs to grow by 11-14%. Zimmer predicts growth in North and South America to be above its overall increase, but that Europe and Asia Pacific will be below the average rate. Reconstructive implants are set to grow by 10-13%, while fracture management product sales will go up by 6-9%. Zimmer is set to begin trading independently on August 7 following its previously announced spin-off from Bristol-Myers Squibb.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.